Advertisement admin, Author at Pharmaceutical Business review - Page 413 of 458
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by Lavillcok Lavillcok

La Jolla buys GCS-100 rights from Solana

GCS-100 is an inhibitor of galectin-3, a novel molecular target implicated in cancer and chronic organ failure. Galectin-3 plays a key role in the immune system’s response to

Galena initiates Phase III PRESENT trial for NeuVax

The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment (PRESENT) study will enroll approximately 700 breast cancer patients. The

FDA approves TYSABRI label change

The new label identifies anti-JCV antibody status as a risk factor for developing an infrequent but serious brain infection known as progressive multifocal leukoencephalopathy (PML). The new label

BBR receives US patent for CD14 molecule

BBR has continued research in animal models verifying pharmacological properties of the CD14 molecule, the company said. The glycoprotein CD14 on the surface of human macrophages is important